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Streptococcus suis serotype 2 (SS2) induced sepsis and meningitis are often
accompanied by bacteremia. However, the mechanism whereby it helps S. suis to
evade PMN-mediated phagocytosis remain unclear. Because of the central roles of
bacteria-human fibrinogen (hFg) interaction in innate immunity, here, a proteomics based
Far-western blotting (PBFWB) was developed to identify the fibrinogen-binding surface
proteins of S. suis (SsFBPs) on a large-scale. And then thirteen potential SsFBPs were
identified by PBFWB and we selected seven potential surface proteins to further confirm
their binding ability to hFg, of which the genemutant strains of MRP displayed significantly
decrease in binding to immobilized hFg. Additionally, the polyclonal antibodies against
Enolase were found to significantly inhibit the binding of SS2 to hFg. Strikingly, MRP and
Enolase were found to improve the antiphagocytic ability of SS2 to PMNs by interacting
with hFg and enhance the survival of SS2 in human blood. Taken together, the PBFWB
method provides useful clues to the bacteria-host interactions. These studies firstly
disclose MRP and Enolase were involved in immune evasion of SS2 at least in part by
binding to Fg, which make them potential targets for therapies for SS2 infection.
Keywords: Streptococcus suis serotype 2, fibrinogen-binding proteins, interaction, antiphagocytosis, human
blood
Introduction
Streptococcus suis serotype 2 (SS2) infection is one of the major causes of septicemia and meningi-
tis in pigs and humans (Wertheim et al., 2009; Huong et al., 2014), which are often accompanied
by bacteremia (Tang et al., 2006; Wangkaew et al., 2006; Yu et al., 2006). To cause bacteremia,
bacterial pathogens need to evade PMN-mediated innate immunity and maintain a high level
in human blood. Although SS2 has become a public health concern due to the increasing num-
ber of human S. suis cases reported in the literature over the past 10 years (Huong et al., 2014),
little is known about how S. suis resistant to PMN’s phagocytosis and its survive in the host
blood.
For the establishment of survive and dissemination in blood, bacteria must ﬁrst inter-
act with host proteins in blood followed by a variety strategies for avoiding host immunity.
Fibrinogen (Fg) is a heterogeneous dimerica plasma glycoprotein protein composed of three
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pairs of non-identical peptide chains named Aα, Bβ , and γ .
Fg also participates in the innate immune defense through
interactions with leukocytes that support leukocyte activation
events and delay apoptosis (Rubel et al., 2001). Numerous Fg-
binding proteins (FBPs) in Gram-positives have been identiﬁed,
including the Group A streptococci (GAS)M proteins (Carls-
son et al., 2005; Courtney et al., 2006) and serum opacity
factor (SOF) protein (Courtney et al., 2002); Group B strep-
tococci (GBS) FbsA (Pierno et al., 2006); Group G strep-
tococci (GGS) FOG (Johansson et al., 2004); staphylococcal
Fg-binding microbial surface component recognizing adhe-
sive matrix molecules(MSCRAMMs): ClfA, SdrG and FnbpA
(Deivanayagam et al., 2002; Ponnuraj et al., 2003; Keane et al.,
2007). Although many of these proteins employ distinct Fg-
binding mechanisms (Rivera et al., 2007), the end result is to
manipulate Fg’ s biology to enhance the microbe’s survival in
the host. In many cases these FBPs act as virulence factors that
involved in innate immunity such as GAS avoiding phagocyto-
sis byM protein to inhibit the complement activation (Carlsson
et al., 2005; Courtney et al., 2006), FOG induced the bacteria
aggregation (Johansson et al., 2004), interference the recogniza-
tion signal of phagocyte cells by Efb in Staphylococcus aureus
(Ko et al., 2011), formation of a semi-ﬂexible polymer-like net-
work by interacting with FbsA in Streptococcus agalactiae, which
becomes an eﬃcient mask against phagocytic clearance (Pierno
et al., 2006). Generally, FBPs were identiﬁed by Far-western blot-
ting such as ClfA (Wann et al., 2000), FnbpA (Wann et al.,
2000), SdrG (Davis et al., 2001), FAI (Talay et al., 1996) in
Group C streptococci (GCS) and FbsA (Schubert et al., 2002).
Moreover, the linear binding sequence were identiﬁed in FbsA
(Schubert et al., 2002) and FAI (Talay et al., 1996), respec-
tively, suggesting that a proteomics based Far-western blotting
(PBFWB) could be developed to identify FBPs in pathogens on
a large-scale.
It has been suggested that numerous surface proteins of
pathogens are crucial for pathogenesis. In silico analysis of the
genome of the Chinese SS2 reference strain 05ZYH33 revealed
33 putative cell-wall-anchored proteins containing LPXTG-or
related motif (Wang et al., 2009). Thus, far, only an adhesin
FBPs was reported to bind Fg (De Greeﬀ et al., 2002). How-
ever, it remains to be determined whether or not these sur-
face proteins play critical roles in the survival of S. suis in host
blood.
In the present study, we developed a proteomics based
Far-western blotting analysis to identify the novel ﬁbrinogen-
binding surface proteins of S. suis (SsFBPs) on a large-scale.
Seven important potential SsFBPs were further compared their
binding ability to hFg; of which, MRP (muramidase-released
protein) and Enolase were identiﬁed as important FBPs in the
high virulent SS2 strain 05ZYH33. Surprisingly, MRP and Eno-
lase were found to mediate the antiphagocytosis of S. suis to
PMNs by interacting with hFg. MRP is an important epidemic
marker with unknown mechanism in pathogenesis. Enolase is
a surface antigen of S. suis, however, the precise contribution
of Enolase to bacterial virulence is unknown. These results may
provide useful insights for understanding the pathogenesis of
S. suis.
Experimental Procedure
Bacterial Strains and Growth Conditions
One SS2 strain 05ZYH33 (Chen et al., 2007), originally isolated
from a dead STSS patient in an outbreak in Sichuan, China, 2005
was selected in this study. The S. suis strain was maintained on
Columbia blood agar supplemented with 5% sheep blood and
the inoculum was cultured in Todd-Hewitt broth (THB) at 37◦C
and harvested at stationary growth phase for experimentation.
A total of 100μg/ml spectinomycin (Spc) (Sigma), 5μg/ml
chloromycetin (Cm) and 8μg/ml erythromycin (Em) was used
for the S. suis transformants, and 50μg/ml of ampicillin (Amp)
(Sigma) was applied to screen E. coli transformants. The commer-
cial pMD18-T vector (Takara) or pEASY-T1 (TransGen Biotech)
was utilized to clone PCR fragments for direct sequencing of
gene. E. coli DH5α cells were maintained in Luria–Bertani (LB)
broth or agar medium at 37◦C for recombinant plasmid ampliﬁ-
cation. Bacterial strains and plasmids used in this study are listed
in Table 1.
Ethics Statement
The healthy donors who provide the serum and plasma in
the 307 hospital in this study provided written informed con-
sent in accordance with the Declaration of Helsinki. Approval
was obtained from the medical ethics committee of the 307
hospital.
Identification of Novel SsFBPs by Proteomics-Based
Far-Western Blotting (PBFWB)
The cell wall proteins (CWPs) used for proteome analysis was
prepared as previous described (Geng et al., 2008). Brieﬂy, bac-
terial pellets were resuspended in a separation buﬀer contain-
ing 30mM Tris-HCl (pH 7.5), 3mM MgCl2, 25% sucrose and
mutanolysin (125U/ml) and incubated for 1.5 h at 37◦C. The
protoplast fraction was separated by centrifugation at 12,000 rpm
for 10min at 4◦C, and the supernatant containing CWPs was
subject to the acetone-TCA precipitation. The CWPs were sol-
ubilized in a buﬀer containing 7MUrea, 2M Thiourea, 4% (w/v)
CHAPS, 50mM DTT and protease inhibitor cocktail. Protein
concentrations were determined by the PlusOne 2-D Quant Kit
(GE Healthcare).
The 2-DE experiment was carried out as previously described
(Jing et al., 2008). Brieﬂy, 18−mm immobilized pH gradient
strips (pH 4-7; GE Healthcare Waukesha, WI, USA) were used
in the isoelectric focusing (IEF) analysis, in which, 1mg cell wall
proteins resuspended in 350μl rehydration buﬀer [7MUrea, 2M
thiourea, 4% (w/v) CHAPS, 50mM DTT] was loaded. For lig-
and blot analysis, the 2-DE gel was transferred to polyvinylidene
diﬂuoride (PVDF) membranes (Millipore), which were blocked
with 5% w/v nonfat dry milk at 4◦C for 12 h and incubated
with 5μg/ml hFg (Merck) for 1 h at room temperature, washed
three times with Tris-buﬀered saline with Tween 20 (TBST)
and incubated with HRP conjugated goat anti-hFg polyclone
antibody (1:20000) (Abcam). The negative control group was
incubated with TBST containing 1% BSA (-hFg). Positive spots
were detected by enhanced chemi-luminescence western blotting
detection reagents (Thermo Scientiﬁc, Waltham, MA, USA) and
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TABLE 1 | Bacterial strains and plasmids used in this study.
Strain or plasmid Descriptiona or sequence Source, reference, PCR products
E. coli DH5α Host for cloning vector In this lab
05ZYH33 Virulent Chinese S. suis serotype 2 isolate In this lab
MRP Gene mrp knockout mutant strain; CmR This study
Fhb Gene fhb knockout mutant strain; CmR Pian et al., 2012
Ssads Gene ssads knockout mutant strain; CmR Liu et al., 2014
1538 Gene 1538 knockout mutant strain; CmR This study
1083 Gene 1083 knockout mutant strain; CmR This study
Plasmids Description
pMD18-T TA cloning vector, lacZ, AmpR TaKaRa
pEASY-T1 TA cloning vector, lacZ, AmpR TransGen Biotech
pSET1 S. suis-E. coli shuttle vector, CmR Takamatsu et al., 2001
pSET4s Gene replacement vector with MCS of pUC19, SpcR Takamatsu et al., 2001
pSET4s:: mrp The gene mrp knockout plasmid, SpcR CmR This study
pSET4s:: 1538 The gene 1538 knockout plasmid, SpcR CmR This study
pSET4s:: 1083 The gene 1083 knockout plasmid, SpcR CmR This study
Primers Sequenceb (5′–3′) PCR products
mrp KOP1 CCCAAGCTTTGGAACGTGAGCGTTTGGCAAG The mrp gene and its upstream flanking regions
mrp KOP2 CCTCGGAACCCATCGAATTACGACACACCAAGCAAAACG
mrp KOP5 CATCAAGCTCTAGTTCGGTGTACTGGTGAGGCTTCATCTG The mrp gene and its downstream flanking regions
mrp KOP6 CGCGGATCCCTCAAAGGATAGAGAGTTTGGAGCA
mrp-F GGAGCTGAAGTTGATGCCT A fragment of mrp gene
mrp-R GGTCGTTCTCCACAATTTCACG
1538KOP1 GCAGGATCCAAAGAAGCCTTCACTGCAG The 1538 gene and its upstream flanking regions
1538KOP2 CCTCGGAACCCATCGAATTAAGCTTGTGTTGCAATAACGC
1538KOP5 CATCAAGCTCTAGTTCGGTGATACCGGTCAAGAAGC The 1538 gene and its downstream flanking regions
1538KOP6 GCGGAATTCGTTATGAAGTCTTCGGCGC
1538-F GGACTTGATGAGTATAACCG A fragment of 1538 gene
1538-R GCCCGTTGTACCGTTTGTAT
1083KOP1 GCAGGATCCGTGCAGTTCTTGTAGCTAAGACAGG The 1083 gene and its upstream flanking regions
1083KOP2 CCTCGGAACCCATCGAATTAGATGCTTCTGAGCT
1083KOP5 CATCAAGCTCTAGTTCGGTGGGTGTTGAATTGGCAG The 1083 gene and its downstream flanking regions
1083KOP6 GCGGAATTCCACCGCTTGTAGGTTCC
1083-F TGTGTTCGGTATTGGTTTTGCC A fragment of 1083 gene
1083-R TGTACCTTCTGCTGATTGG
CM-F TAATTCGATGGGTTCCGAGG Chloramphenicol resistant gene
CM-R CACCGAACTAGAGCTTGATG
SPC-F GTGTTCGTGAATACATGTTATA Spectinomycin resistant gene
SPC-R GTTTTCTAAAATCTGATTACCA
aAmpR, ampicillin resistant; CmR, chloramphenicol resistant; Spcr , spectinomycin resistant; EmR, erythromycin resistant.
bThe underlined sequences are the restriction sites.
by exposing themembrane to X-ray ﬁlm(Fuji photo ﬁlm) at room
temperature for 30–120 s.
MALDI-TOF-MS to Identification of Positive
Spots
The positive protein spots in-Gel (the corresponding spots to
Far-western blotting) digestion were carried out as described pre-
viously (Geng et al., 2008). Peptides from digested proteins were
resolubilized in 2μl of 0.5% triﬂuoroactic acid. TheMALDI-TOF
MS measurement was performed on a Bruker Reﬂex III MALDI-
TOF MS (Bruker Daltonics, Germany) operating in reﬂectron
mode with 20 kV accelerating voltage and 23 kV reﬂecting volt-
age. A saturated solution of R-cyano-4-hydroxy-cinnamic acid
in 50% acetonitrile and 0.1% triﬂuoroactic acid was used as the
matrix. Onemicroliter of thematrix solution and sample solution
at a ratio of 1:1 was applied onto the Score384 target well.
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Database Searching was performed as described previ-
ously (Geng et al., 2008), to avoid inaccurate annotations
derived from single genome or divergent protein sequences
between strains, we established a local database including
all the predicted protein sequences of three SS2 strains
98HAH33, 05ZYH33, and P1/7. Peptide mass ﬁngerprints
(PMFs) were searched by the program Mascot (Matrix Science
Ltd.) licensed in-house against this local combined database,
and the results were checked using Mascot with free access
on the Internet (http://www.matrixscience.com) against NCBInr
database.Monoisotopicmasses were used to search the databases,
allowing a peptide mass accuracy of 0.3 Da and one partial
cleavage. Oxidation of methionine and carbamidomethyl mod-
iﬁcation of cysteine was considered. For unambiguous identiﬁ-
cation of proteins, more than 5 peptides must be matched for
MALDI-TOF data.
Cloning, Expression, and Purification of Recombinant
Potential SsFBPs
Seven potential surface SsFBPs were selected to be recombinant
expressed, of which, six proteins were expressed the whole-length
protein. MRP-N (N-terminus of MRP, a.a. 48–721) was expressed
because the full length MRP protein was not easily water-soluble
expressed. To express recombinant potential SsFBPs proteins in
E. coli, genomic DNA isolated from S. suis strain 05ZYH33 was
used as template for all PCRs using the oligonucleotide primers
described in Supplemental Table S1. PCR products were digested
and ligated into the PET-28a vector (GEHealthcare). The ligation
mixture was transformed into E. coli BL-21 (Stratagene), grown
on a LB agar plate containing 100μg/ml kanamycin to select
for transformants. Insertions were conﬁrmed by DNA sequenc-
ing. Expression of fusion proteins was induced by adding 1mM
IPTG when cultures had grown to an A600 of 0.4–0.6. After the
cell growth continued for another 4 h at 37◦C, an aliquot of 1ml
was harvested. The induced proteins were puriﬁed from cultures
growing at 30◦C for 7 h by Ni-chelating chromatography (GE
Healthcare) according to the manufacturer’s recommendations.
Preparation of the Anti-Enolase Sera and IgG
To generate polyclonal antibodies against Enolase, puriﬁed
Enolase recombinant proteins were injected subcutaneously
into two female rabbits as previously described (Geng et al.,
2008). Serum from the immunized rabbits was collected.
The preimmune IgG and the anti-Enolase IgG were puri-
ﬁed from the preimmune serum and the immune serum,
respectively, by aﬃnity chromatography (Pierce, Rock-
ford, IL, USA) according to the manufacturer’s instructions
(Pierce).
ELISA-Type Binding Assay
To detect the binding of hFg to immobilized potential SsFBPs, 96-
well immulon microtiter plates (Thermo Scientiﬁc) were coated
overnight at 4◦C with 100μL of 5μg/ml potential SsFBPs. After
blocking the wells with 3% BSA in PBS, 100μL of hFg (1–
10μg/ml, Merck) were added, and the plates were incubated for
1 h. Frequently, the plates were washed three times with PBST
(Phosphate-buﬀered saline with 0.05% Tween-20) and incubated
with HRP conjugated goat anti-hFg polyclone antibody (1:20000,
Abcam). The negative control group was incubated with PBST
containing 1% BSA, without hFg (0μg/ml hFg). The binding was
quantiﬁed after adding the substrate o-phenylenediamine dihy-
drochloride (Sigma) by measuring the resulting absorbance at
450 nm in a ThermoMax ELISA microplate reader (Molecular
Devices).
Generation of the Gene Mutant of Potential SsFBPs
DNA fragments corresponding to the upstream and downstream
regions of the genes encoding potential SsFBPs were ampli-
ﬁed using primers pairs described in Table 1. The Cm cas-
sette was ampliﬁed from plasmid pSET1 with primers CM-
F/CM-R. The primers pairs (Table 1) were designed to be
fused as an intact fragment by overlap extension PCR. PCR
amplicons were cloned into the temperature-sensitive S. suis-
E. coli shuttle vector pSET4s, giving rise to the knockout vec-
tor pSET4s::ssfbps. The procedures for the selection of mutants
by double cross-over were described previously (Takamatsu
et al., 2001). The resulting mutant strain was veriﬁed by PCR
using three pairs of primers (Table 1) and direct DNA sequenc-
ing analysis of the mutation sites using genomic DNA as
template.
Binding of S. suis to Immobilized Fibrinogen
Binding of S. suis to immobilized ﬁbrinogen was detected as pre-
viously described (Seo et al., 2012). Puriﬁed ﬁbrinogen (100μl
of 1, 5, 10μg/ml ) or BSA (100μl of 1, 5, 10μg/ml) was
immobilized in 96-well microtiter dishes by overnight incuba-
tion at 4◦C and washed four times with PBS. Overnight cultures
of the WT and the mutant strains were harvested by centrifu-
gation and adjusted to almost equal original inoculum (con-
centration of ∼ 105 CFU/ml) in PBS. The wells pretreated with
hFg/BSA were and then incubated with 100μl of S. suis sus-
pension for 30min at 37◦C. The wells were then washed four
times with PBS to remove unbound bacteria, and then treated
with 100μl of trypsin (2.5mg/ml) for 10min at 37◦C to release
the attached bacteria. The number of bound bacteria was deter-
mined by plating serial dilutions of the recovered bacteria onto
THB agar plates.
PMN Killing Assays
PMNs are the ﬁrst line of defense against bacterial infections in
human blood. To determine whether the interaction between
SS2 and hFg has an impact on the antiphaocytosis ability of
SS2, bacterial growth was measured in the presence of PMNs
suspended in fresh plasma, fresh serum, or fresh serum supple-
mented with hFg. In PMN killing assay, PMNs were isolated
from heparinized venous blood as described by Baltimore et al.
(1977). Killing experiments of SS2 by PMNs were carried out as
described previously (Pian et al., 2012). PMNs were infected with
SS2 at MOI 1:15 (PMN: bacterium) in 50% non-immune human
serum (or 50% human plasma, 50% serum supplemented with
hFg) and centrifuged at 380 rpm for 5min at 4◦C. The plates were
incubated at 37◦Cunder 5%CO2for 60min, samples were treated
with 1% saponin and diluted, which were then plated onto blood
agar. Colonies were counted and the percentage of surviving
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SS2 was calculated as follows: (CFU PMN+/CFU PMN−) × 100%.
In antibodies blocking assay, the polyclonal antibodies against
MRP-N or Enolase were preincubated with bacteria at 37◦C for
15min at room temperature before bacteria were added to PMNs.
Bactericidal Assays by Human Blood
The bactericidal assays were used to compare the viability of
WT and ssfbps mutant growth in human blood. Lanceﬁeld
bactericidal assays were performed as described previously (Yam-
aguchi et al., 2006). Brieﬂy, diluted cultures ofWT,mutant (50μl,
∼104 CFU/ml) were combined with fresh human blood (450μl)
and the mixtures were rotated at 37◦C. At which time aliquots
were incubated on ice for 20min in a ﬁnal concentration of 0.1%
saponin to lyse eukaryotic cells. Viable cell counts were deter-
mined by plating diluted samples onto blood agar. The percent of
live bacteria was subsequently calculated as (CFU on plate/CFU
in original inoculum)× 100%. The data are presented as mean±
SD from three separate experiments.
Statistical Analysis
Unless otherwise speciﬁed, all the data were expressed as
means ± standard deviations. Diﬀerences between the wild-type
strain and the isogenic mutant was analyzed using the unpaired
two-tailed Student t-test. For all tests, a value of P< 0.05 was con-
sidered as the threshold for signiﬁcance. All statistical tests were
carried out using SPSS 15.0.
Results
The hFg Enhances the Survival of SS2 in
PMN-killing Assay
PMNs are the ﬁrst line of defense against bacterial infections in
human blood. To determine whether the interaction between SS2
and hFg has an impact on the survival of SS2 in PMNs killing
assay, bacterial growth was measured in the presence of PMNs
suspended in fresh plasma, fresh serum, or fresh serum supple-
mented with hFg, which is themain protein extracted when blood
is clotted to produce serum. 05ZYH33 had superior growth when
cultured with PMNs suspended in plasma as compared to serum
(Figure 1A), with the addition of puriﬁed hFg at physiologi-
cal concentrations (2–4mg/ml) to the serum further enhancing
growth (Figure 1B), suggesting that hFg is an important com-
ponent that is required for SS2 to resist phagocytosis in human
blood and potential contributions of FBPs to this resistance.
Identification of Novel SsFBPs by
Proteomics-Based Far-Western Blotting (PBFWB)
To identify candidate SsFBPs contributing to the antiphago-
cytic activity of SS2, a proteomics-based Far-western blotting
method was developed in the present study. Cells cultured in
Todd Hewitt broth (THB) for 8 h before collection. Concen-
trated CWPs samples were analyzed by two-dimensional elec-
trophoresis (2-DE) image analysis and Fg-binding positive spots
were identiﬁed by Far-western blotting. Consistent with our pre-
viously study (Geng et al., 2008), more than 300 Coomassie-
stained protein spots were detected on the 2-DE gel (Figure 2A)
and 18 spots were detected by Far-western blotting (Figure 2B).
No strong response spots were seen in the negative control (the
transferred PVDF membrane was incubated in TBST containing
1% BSA without hFg). A total of 16 positive spots representing
13 proteins were identiﬁed by matrix-assisted laser desorp-
tion/ionization time-of-ﬂight mass spectrometry (MALDI-TOF
MS), as summarized in Table 2. Four proteins MRP, Fhb, Ssads
and SSU05_1538 (HP1538) were predicted to be cell wall proteins
based on the presence of the LPxTG motif typical of the
membrane-anchored surface proteins in Gram-positive bacte-
ria, of which MRP, factor H-binding protein (Fhb) and S. suis
FIGURE 1 | Role of fibrinogen in resistance of S. suis to phagocytosis.
Viability of S. suis was enhanced in the presence of hFg, as determined by
the PMN killing assay. The bacteria were co-incubated with PMNs at a MOI
of 1:15 (PMN:bacterium) in 50% serum(S), 50% fresh plasma (P) or 50%
serum supplemented with hFg 1, 2, or 4mg/ml. At 60min, PMNs were lysed
by 1% saponin and bacteria were plated on solid agar medium. The
percentage of viable bacteria was calculated as (CFU PMN+/CFUPMN−) ×
100%. Significant differences were noted between the serum and the plasma
(A), or the serum (0mg/ml hFg) and the serum supplemented with hFg at
physiological concentrations (2–4mg/ml) (B). The serum and plasma isolated
from the same healthy donor. Data are expressed as the mean ± SD of three
independent experiments. hFg, human fibrinogen.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 March 2015 | Volume 5 | Article 19
Pian et al. Novel fibrinogen-binding proteins of Streptococcus suis
FIGURE 2 | 2-DE profile (A) and Far-western blotting (B) identification
of SsFBPs of S. suis CWPs. The CWPs were separated in the first
dimension (18 cm) by isoelectric focusing (IEF) in the pI range of 4–7 and by
12.5% SDS-PAGE in the second dimension. Arrows indicate potential
SsFBPs recognized with HRP-anti human Fg polyclonal antibody. CWPs, cell
wall proteins; SsFBPs, S. suis, fibrinogen-binding proteins.
TABLE 2 | Identification of the potential SsFBPs by MALDI-TOF MS.
Spot IDa Scoreb Locusc GI Product Cellular locationg Sequence Matched
coveraged (%) peptidese
CW1 472 SSU05_0753 gi|146318407 MRP Cell wallh 38 33
CW2 111 SSU05_0272 gi|146317928 Fhb Cell wallh 26 13
CW3 148 SSU05_0272 gi|146317928 Fhb Cell wallh 27 14
CW4 214 SSU05_1000 gi|146318654 Putative 5′-nucleotidase Cell wallh 44 18
CW5 238 ssu05_1538 gi|146319192 Putative 5′-nucleotidase Cell wall 40 29
CW6 285 SSU05_1868 gi|146319522 Peptide ABC transporter, peptide-binding protein Non-Cytoplasmic 58 22
CW7 241 SSU05_1868 gi|146319522 Peptide ABC transporter, peptide-binding protein Non-Cytoplasmic 63 23
CW8 295 SSU05_1503 gi|146319156 Enolase Cytoplasmich 60 22
CW9 241 SSU05_0155 gi|146317813 Glyceraldehyde-3-phosphate dehydrogenase Cytoplasmich 56 18
CW10 260 SSU05_0252 gi|146317908 gdhA; NADP-specific glutamate dehydrogenase Cytoplasmic 48 24
CW11 361 SSU05_2086 gi|146319740 High-affinity zinc uptake system protein znuA precursor Non-Cytoplasmic 42 13
CW12 257 SSU98_0330 gi|146320177 Fructose-bisphosphate aldolase Cytoplasmic 39 10
CW13 521 SSU05_0152 gi|146317810 Elongation factor G Cytoplasmic 42 27
CW14 482 SSU05_1548 gi|146319202 Hypothetical protein Non-Cytoplasmic 33 13
CW15 696 SSU05_0152 gi|146317810 fusA; elongation factor EF-G Cytoplasmic 43 26
CW16 UIf UIf
CW17 UIf UIf
CW18 327 SSU05_1083 gi|146318737 ABC transporter periplasmic protein Non-Cytoplasmic 40 11
a Spots referring to Figure 2.
bTotal protein score based on combined mass and mass/mass spectra.
cThree different kinds of loci in the genome annotations of three S. suis strains (98HAH33, 05ZYH33, and P1/7) are used. Proteins with high homology were assigned with a locus in
the genome annotation of the 98HAH33 strain.
dPercentage of the identified sequence to the complete sequence of the known protein.
eAll the spots had high-probability results by MASCOT search, and there is at least one peptide analyzed by MS/MS in each spot.
fUnidentified.
gCellular location was predicted by PSORTb (http://www.psort.org/psortb/index.html).
hWhich have been reported as surface proteins.
adenosine synthase (Ssads) have been reported as surface pro-
teins for SS2 (Chen et al., 2010; Zhang et al., 2011; Liu et al.,
2014). Two cytoplasmic enzymyes Enolase and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) have also been documented
as surface proteins involved in SS2 adherence (Wang and Lu,
2007; Feng et al., 2009). As an adhesin, Enolase also binds
to ﬁbronectin (Esgleas et al., 2008); indeed, most ﬁbronectin-
binding proteins also bind Fg in bacteria (Piroth et al., 2008;
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FIGURE 3 | Identification the binding of fibrinogen to FBPs of S. suis.
(A) The hFg-binding capacity of recombinant SsFBPs was assessed by
Far-western blotting; hisFhb, hisSsads, hisMRP-N, his1083, hisenolase,
his1538, and his1868 were separated by SDS-PAGE and then transferred to
PVDF and incubated with hFg (5μg/ml). Bound hFg was detected with HRP
conjugated anti-hFg antibody. (B) Microtiter wells were coated with purified
recombinant putative SsFBPs and reacted with the indicated concentrations
of hFg. The negative control was the incubation of immobilized recombinant
SsFBPs with PBST containing 1% BSA, but without hFg (0μg/ml). Bound
hFg was detected with HRP conjugated anti-hFg antibody. Data are
expressed as the mean ± SD of three independent experiments. (C) Binding
of the WT and the ssfbp mutants SS2 to immobilized hFg. SS2 strains WT
and the ssfbp mutants (∼1× 104 CFU per well) were incubated with wells
coated with hFg or BSA (1, 5, 10μg/ml per well). Data are expressed as the
mean ± SD of three independent experiments. (D) Binding of WT SS2 to
immobilized hFg after blocked with specific antibodies. SS2 strains WT
(∼1× 104 CFU per well) that had been pretreated with preimmune IgG or the
anti-Enolase IgG were incubated with wells coated with hFg (1, 5, 10μg/ml
per well). Values represent the Data are expressed as the mean ± SD of
three independent experiments. WT, wild-type (05ZYH33); MRP, the
isogenic mutant strain of mrp; 1538, the isogenic mutant strain of 1538;
1083, the isogenic mutant strain of 1083; Fhb, the isogenic mutant strain
of fhb; Ssads, the isogenic mutant strain of ssads. MRP-BSA, the binding
of MRP strains to BSA (control to hFg).
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Burke et al., 2010). Three proteins SSU05_1868 (HP1868),
SSU05_1869, and SSU05_1083 were putative ATP-binding cas-
sette transporters, which are often transmembrane proteins in
Gram-positive bacteria. Three cytoplasmic proteins SSU05_0252,
SSU98_0330, and SSU05_0152 (annotated as glutamate dehydro-
genase, fructose-bisphosphate aldolase and elongation factor G,
respectively) could be due to contamination released by dead
bacteria. These results provide a global view of hFg-binding pro-
teins in SS2 and clues to the function of SsFBPs in SS2-induced
pathogenesis.
Confirmation of the Interaction of hFg with
SsFBPs
We selected the above seven potential surface SsFBPs for recom-
binant expression and further compare their ability to bind-
ing to hFg by Far-western blotting or ELISA-type binding
assay. A strong response to hFg was detected for of the N-
terminus of MRP (hisMRP-N, a.a. 48–721) and hisEnolase by
Far-western blotting (Figure 3A). The ability of hisSsads, hisFhb,
his1083, his1538, his1868, hisMRP-N, and hisEnolase to bind hFg
was further evaluated by ELISA-type binding assay, hisMRP-
N,hisEnolase,his1868, his1538, andhis1083 showed concentration-
dependent binding to Fg (Figure 3B); with similar results to
Far-western blotting, hisMRP-N andhis Enolase displayed strong
binding to hFg. Obviously, OD450 of MRP and Enolase group
was 4-fold and 3-fold than Fhb at 10μg/ml hFg, suggesting that
MRP and Enolase were the important SsFBPs; but 1868, 1083,
and 1538 also bound ﬁbrinogen to a signiﬁcant degree. However,
the recombinant SsFBPs couldn’t reﬂect the genuine abundance
of proteins on bacteria. Considering most of the gene encod-
ing these SsFBPs don’t lie in close proximity of phage-associated
genes with their independent promoters, it’s therefore to con-
struct the gene knockout mutants of these SsFBPs and evaluate
the binding ability of WT and these ssfbps mutants to immobi-
lized hFg. Interestingly, the results indicate the mutant MRP,
in which MRP was inactivated, bound dramatically less ﬁbrino-
gen than the parent strain (Figure 3C). Enolase is a functionally
important enzyme in both prokaryotic and eukaryotic organisms
(Gerlt et al., 2012) and its gene can’t be knock out, the spe-
ciﬁc antibody-blocking assay was used in this study. The results
showed that the polyclone antibody against the Enolase signiﬁ-
cantly decreased the adhesion of 05ZYH33 to hFg, respectively,
while the preimmue IgG, as control, almost had no eﬀect on
these adhesion (Figure 3D), which is consistent with the result
of ELISA-binding assay. The protein 1868 was not further stud-
ied for it’s diﬃcult to acquire its speciﬁc antibody and its mutant
strain. These results suggest that MRP and Enolase are the major
FBPs on SS2, they would possibly play some roles in SS2-induced
pathogenesis.
MRP and Enolase Increase Antiphagocytic
Activity of SS2 to PMNs by Interacting with hFg
To determine whether the SsFBPs-hFg interactions have impacts
on the antiphaocytosis ability of SS2, bacterial growth was mea-
sured in the presence of PMNs suspended in fresh plasma, fresh
serum, or fresh serum supplemented with hFg. The data indi-
cated that themrpmutantMRP, not the 1083 and 1538 mutant,
FIGURE 4 | MRP and Enolase improve the antiphagocytic ability of SS2
by interacting with hFg. (A) The MRP-hFg interaction enhanced the survival
of SS2 in PMN killing assays. WT, MRP, 1538, and 1083 strains were
co-incubated with PMNs at a MOI of 1:15 (PMN:bacterium) in 50% serum
without or with hFg (2mg/ml) for 60min. The mutant MRP significantly
reduced viability compared to WT in both plasma and serum containing hFg at
physiological concentrations (2mg/ml), but not in serum alone. Specific
antibodies against Enolase (B) significantly decrease the viability of SS2 in
plasma or serum sulpplemented with hFg, but not in serum alone. Bacteria
that pretreated with preimmune IgG (control), or anti-Enolase IgG were
co-incubated with PMNs at a MOI of 1:15 (PMN:bacterium) in 50% serum
without or with hFg (2mg/ml) for 60min. The percentage of viable bacteria
was calculated as (CFU PMN+/CFUPMN−) × 100%. Data are expressed as the
mean ± SD of three independent experiments. WT, wild-type (05ZYH33);
MRP, the isogenic mutant strain of mrp; 1538, the isogenic mutant strain of
1538; 1083, the isogenic mutant strain of 1083.
was found to be more killed than the WT 05ZYH33 in plasma
or serum supplemented with hFg oposonized PMNs, but not
in serum alone (Figure 4A). Additionally, in a speciﬁc antibody
blocking assay, comparing to preimmune serum, the antiserum
against the Enolase (Figure 4B) decreased the bacteria survival
in plasma or serum supplemented with hFg at physiological
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concentrations (2mg/ml), but had no eﬀect in serum alone.
These results indicate that, among SsFBPs, MRP and Enolase
are responsible for improving antiphagocytic ability of S. suis by
interacting with hFg. Fhb and Ssads were reported as FH-binding
protein and adenosine synthase of SS2 in our previous study,
respectively; they also play important roles in immune evasion
in human blood, therefore not be studied in the present study.
MRP and Enolase Enhance the Survival of SS2 in
Human Blood
PMNs are the major phagocytes with defense against bacteria in
host blood; the SsFBPs-hFg interaction improving the antiphago-
cytic ability of SS2 to PMNs suggest that these SsFBPs possibly
contribute to the survival of SS2 in host blood. We performed
bactericidal assays to test for the growth of WT and ssfbp-mutant
strain or the strain with speciﬁc antibody-blocking in healthy
non-immune human blood from diﬀerent donors. As expected,
it’s MRP, not 1538 and 1083, reduced the viability com-
pared to WT (Figure 5A). Additionally, in a speciﬁc antibody
blocking assay, the polyclone antibody against Enolase decrease
the WT survival in human blood (Figure 5B), suggesting that
MRP and Enolase play important roles in immune evasion of
SS2 in host blood.
Discussion
Streptococcus suis is an emerging pathogen to leading cause of
skin wounds, blood-stream, brain (Segura, 2009). To survive in
blood, Gram-positive pathogenic bacteria must escape a variety
of innate immune mechanisms, such as complement-mediated
phagocytosis. However, the mechanism of S. suis survival in
human blood is largely unclear and few virulence factors were
found to be involved in escaping innate immunity in host blood
for SS2 such as Fhb and Ssads in our previous study (Pian et al.,
2012; Liu et al., 2014).
Some surface proteins have been reported to bind to Fg in
GAS and GBS that are involved in bacteria pathogenesis (Court-
ney et al., 2006; Pierno et al., 2006; Seo et al., 2012). Our results
now demonstrate that hFg promotes the survival ability of SS2
in PMN-killing assay. However, the interaction between SS2 and
hFg remained unclear, which may be mediated the surface pro-
teins of SS2. In this work, we identiﬁed potential SsFBPs with
proteomics based far-western blot method (PBFWB). Thirteen
putative Ssfbps were identiﬁed, among those proteins, there are
four proteins were predicted with a cell wall attachment consen-
sus motif LPxTG; of which, three proteins (MRP, Fhb and Ssads)
and two cytoplasmic enzymes (Enolase and GAPDH) have been
reported as surface proteins for SS2 in previous studies (Wang
and Lu, 2007; Feng et al., 2009; Chen et al., 2010; Zhang et al.,
2011; Liu et al., 2014). The known ﬁbrinogen-binding proteins of
S. suis, FBPs (De Greeﬀ et al., 2002), was not found by PBFWB,
which might be due to its low abundance in the cell wall. The
above ﬁve surface proteins and two putative ABC transporters
(SSU05_1083 and SSU05_1868) were further compared their
binding abilities to hFg. Interestingly, two proteins Enolase and
MRP displayed strongly binding ability to hFg and proved to be
the major SsFBPs on SS2. Moreover, among these proteins, only
the isogenic mutant strain of mrp displayed decreased survival
FIGURE 5 | MRP and Enolase contribute to the survival of SS2 in
human blood. (A) Viability of the ssfbp mutant strains in whole human
blood. Bacteria (50μl, at ∼2× 104 CFU/ml) were added to heparinized
whole blood (450μl) and then gently mixed for 60min at 37◦C. The bacterial
CFU in human blood was determined by THB plates. Each symbol
represents the percentage of live bacteria isolated from individual human
blood. The percentage of live bacteria was subsequently calculated as (CFU
on plate/CFU in original inoculum) × 100%. The horizontal lines indicate the
mean for each group. Antibodies against Enolase (B) decrease the viability of
SS2 in human blood. Bacteria were pretreated with preimmune sera
(control), or anti-Enolase sera from rabbit (1:5 dilution). Each symbol
represents the CFU/ml isolated from individual human blood. Horizontal lines
indicate the mean for each group. Significant differences were found
between preimmune serum and anti-Enolase serum blocking.
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ability compared to the WT strain in the PMN killing assay in
the presence of hFg; and the anti-enolase antibody decreased the
05ZYH33 survival in the presence of hFg in the PMNkilling assay
(Figure 4).
The muramidase-released protein (MRP), a 136-kDa protein,
apart from being associated with the bacterial cell wall of S. suis
with LPxTG motif, MRP is also released from the surface and
detected in culture supernatants (Vecht et al., 1991), which is
often reported as good markers of infection in Europe and Asia
in epidemiology (Vecht et al., 1996; Yang et al., 2006; Rehm
et al., 2007) but with low similarity to other function-known
proteins by amino acid sequence analysis. Moreover, the con-
tribution of MRP to bacterial virulence remained controversy
because this protein was reported as not a critical virulence fac-
tor in an intranasally infection model in Anthony piglets (Smith
et al., 1996). Here, our results now revealed that MRP-hFg inter-
action promotes the antiphagocytosis of SS2 to neutrophils and
then enhances the survival of SS2 in human blood; this process
is likely to be important for the pathogenesis of SS2 but is inde-
pendent of the inhibition of the complement deposition on SS2
(data not shown). However,M proteins were the important FBPs
and virulence factors for GAS, which inhibit the complement
deposition on bacteria surface by binding of hFg to the surfaceM
proteins (Carlsson et al., 2005; Courtney et al., 2006). Considering
the antiphagocytosis roles of MRP in human blood, the contribu-
tion of MRP to the virulence in 05ZYH33 was suggested to be
veriﬁed in an i.v. infection model in piglets.
Similar to GAPDH, enolase is both a cytosolic enzyme of the
glycolysis pathway and a surface adhesion (Feng et al., 2009)
involved in their interactions with plasmin(ogen) (Pancholi and
Fischetti, 1998; Lu et al., 2012) and ﬁbronectin (Esgleas et al.,
2008). However, the role of Enolase in immune evasion remained
unclear until now. In the present study, an intriguing observation
was that enolase contribute to antiphagocytosis of SS2 by inter-
acting with hFg. Moreover, the antibody against Enolase could
decrease the survival of SS2 in human blood. Consisting with
that, Enolase was reported as a surface antigen with signiﬁcant
protection against serotype 2 and 7 intra-peritoneal challenges in
BALB/c mice (Zhang et al., 2009).
In summary, herein, novel FBPs of SS2 were identiﬁed on large
scale by combining proteomic and immune blot; of which, two
SsFBPs (MRP and Enolase) were identiﬁed as important FBPs of
SS2.More interesting,MRP and Enolase contribute to antiphago-
cytic ability of SS2 by interacting with hFg. MRP is an important
infection marker in most Chinese and Europe clinical isolates;
Enolase is a conserve surface antigen among S. suis strains, the
polyclone antibodies against them could decrease the survival of
SS2 in human blood, it is therefore to be promising candidates
for novel therapies for targeting SS2-induced sepsis.
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